Patents by Inventor Frederick M. Hecht

Frederick M. Hecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Physiological Metrics as Candidate Predictors of Antibody Response Following Vaccination Against Covid-19
    Publication number: 20250041403
    Abstract: Methods, systems, and devices are provided for predicting the robustness of an antibody response of a subject to the SARS-COV-2 spike protein receptor binding domain based on measurement of physiological metrics following vaccination. In particular, one or more physiological metrics of the subject selected from dermal temperature deviation, heart rate, respiratory rate, heart rate variability, and deep sleep duration are measured with a wearable device before and after vaccinating the subject, wherein increases in dermal temperature deviation, heart rate, and respiratory rate, and decreases in heart rate variability on the first night after administration of the vaccine to the subject are correlated with greater antibody responses to the SARS-COV-2 spike protein.
    Type: Application
    Filed: December 9, 2022
    Publication date: February 6, 2025
    Inventors: Ashley E. Mason, Frederick M. Hecht, Benjamin Smarr, Patrick Kasl
  • Human Endogenous Retrovirus Polypeptide Compositions and Methods of Use Thereof
    Publication number: 20130323279
    Abstract: The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide.
    Type: Application
    Filed: May 10, 2013
    Publication date: December 5, 2013
    Applicants: The J. David Gladstone Institutes, Albert Einstein College of Medicine of Yeshiva University, The Regents of the University of California, The Governing Counicl of University of Toronto
    Inventors: Douglas F. Nixon, Keith E. Garrison, Duncan A. Meiklejohn, Mario A. Ostrowski, R. Bradley Jones, Ashish Agrawal, Jack Lenz, Seth Rakoff-Nahoum, Frederick M. Hecht
  • Long Interspersed Nuclear Element Polypeptide Compositions and Methods of Use Thereof
    Publication number: 20110046042
    Abstract: The present invention provides LINE polypeptides; and compositions, including immunogenic compositions, comprising a subject LINE polypeptide. The present invention provides a recombinant nucleic acid comprising a nucleotide sequence encoding a subject LINE polypeptide. A subject composition is useful for stimulating a T-cell immune response to a LINE peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers that are associated with tissues in which LINE polypeptides are aberrantly expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a LINE polypeptide.
    Type: Application
    Filed: September 19, 2008
    Publication date: February 24, 2011
    Applicants: THE J. DAVID GLADSTONE INSTITUTES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Douglas F. Nixon, Keith Garrison, Duncan Meiklejohn, Mario Ostrowski, R. Bradley Jones, Ashish Agrawal, Frederick M. Hecht
  • Human endogenous retrovirus polypeptide compositions and methods of use thereof
    Publication number: 20080171061
    Abstract: The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide.
    Type: Application
    Filed: July 19, 2007
    Publication date: July 17, 2008
    Inventors: Douglas Nixon, Keith Garrison, Duncan Meiklejohn, Mario Ostrowski, R. Bradley Jones, Ashish Agrawal, Jack Lenz, Seth Rakoff-Nahoum, Frederick M. Hecht